Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Oct 9, 2014 (12 years ago)

Glimepiride Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Stability Specifications: Micro Labs is recalling two lots due to out of specification results during stability testing.

Cause type: Stability / shelf life

The product degraded or failed stability testing before its labeled expiry. Heat, moisture or time can break the drug down into degradants or reduce potency. All stability / shelf life recalls.

What was recalled

GLIMEPIRIDE TABLETS, USP 2 mg, a)100 count bottle, (NDC 42571-101-01), b) 500 count Bottle (NDC 42571-101-05), Rx only, Manufactured by: Micro Labs Limited, Goa-403 722, INDIA, Manufactured for: Micro Labs USA, Inc., Princeton, NJ 08540

Affected NDCs 42571-0101-01 42571-0101-05

Compare with the code on your package — it is the most precise check available.

Drug: Glimepiride Category: Diabetes Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Glimepiride
NDC 42571-0101
2 mg/1 Tablet
Oral
Micro Labs Limited Rx
Recalling firm
Micro Labs Usa, Inc S
NDC code
42571-101-01
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0046-2015 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Glimepiride recalls

See all
Class III · Low risk

Glimepiride Tablets

Misprint on tablet

Ongoing Other Dr. Reddy's Laboratories, Inc. D-0313-2024
Class III · Low risk

Glimepiride Tablets

Misprint on tablet

Ongoing Other Dr. Reddy's Laboratories, Inc. D-0312-2024
Class II · Moderate risk

Glimepiride USP

CGMP deviations.

Terminated cGMP deviation PD-Rx Pharmaceuticals, Inc. NDC 43063-0587-90 D-0559-2023
Class II · Moderate risk

Glimepiride Tablets USP

cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.

Ongoing cGMP deviation Preferred Pharmaceuticals, Inc. NDC 68788-8066-9 D-0527-2023
Class II · Moderate risk

Glimepiride Tablets

cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.

Ongoing cGMP deviation Preferred Pharmaceuticals, Inc. NDC 68788-8095-9 D-0517-2023

Other recalls by Micro Labs Usa, Inc S

All 2014 recalls
Class III · Low risk

Simvastatin Tablets

Failed Impurities/Degradation Specifications: Product failed a known impurity specification.

Terminated Impurity / degradation Micro Labs Usa, Inc S NDC 42571-080-90 D-0409-2015
Class III · Low risk

Simvastatin Tablets

Failed Impurities/Degradation Specifications: Product failed a known impurity specification.

Terminated Impurity / degradation Micro Labs Usa, Inc S NDC 42571-0040-90 D-0408-2015
Class III · Low risk

Simvastatin Tablets

Failed Impurities/Degradation Specifications: Product failed a known impurity specification.

Terminated Impurity / degradation Micro Labs Usa, Inc S NDC 42571-0020-10 D-0407-2015